Nootropic peptides & brain health

“Nootropic” describes a substance claimed to improve cognitive function — memory, attention, processing speed, or mental energy. Nootropic peptides are short amino-acid chains studied for effects on the brain: neurotrophic signaling, neurotransmitter systems, stress physiology, and sleep. The term is a marketing category, not a pharmacological class. The compounds grouped under it have different mechanisms, different evidence bases, and different regulatory positions.

Most of the peptides discussed as nootropic peptides were developed outside the US — several in Russia, where some are registered medicines — and none is FDA-approved for a cognitive indication. That combination of real clinical history abroad and thin independent evidence is the central fact to understand about the category. For the basics of how peptide therapies work, see what are peptides.

Cognitive function depends on several systems working together. Neurons communicate through electrical signals and chemical transmission across dopaminergic, serotonergic, glutamatergic, GABAergic, and cholinergic pathways — dopamine supports motivation and executive function, acetylcholine memory and attention, glutamate synaptic plasticity, and GABA inhibitory balance.

The brain is also metabolically expensive: it accounts for roughly a fifth of the body’s energy use at about 2% of body weight, so mitochondrial function is tightly coupled to cognitive performance. Cerebral blood flow, hormones (cortisol, thyroid hormone, sex hormones), insulin signaling, neuroinflammation, and oxidative stress all feed into how the brain performs and ages.

Cognitive peptides are studied against pieces of this picture: growth factors such as brain-derived neurotrophic factor (BDNF), neurotransmitter modulation, stress and anxiety circuits, synapse formation, and sleep architecture. None addresses the whole system, which is why the underlying contributors matter first.

Semax and Selank are the two best-known cognitive peptides. Both are short synthetic peptides extended with the same stabilizing Pro-Gly-Pro tail, both were developed in Russia, and both are delivered intranasally there. Semax is built on a fragment of ACTH and is studied for neuroprotection and BDNF signaling; Selank is built on tuftsin and is studied as an anxiolytic that does not sedate.

They are often paired — Semax for focus, Selank for calm — but no published controlled trial has studied them together. Their regulatory paths have also diverged sharply in 2026. The full comparison is in Semax and Selank, and what the Semax research used is covered in Semax dosage.

Among cognitive peptides, Selank is the one studied most directly for anxiety. Published Russian research describes anxiety reduction without the sedation or dependence associated with benzodiazepines, with proposed effects on GABA-A signaling, monoamine metabolism, and neuroimmune cytokines. The evidence is real but narrow: mostly small studies from the developing institutions, with little independent replication.

Sleep and stress are closely linked, which is why DSIP is discussed alongside the cognitive peptides. It has been studied for sleep architecture and cortisol rhythm since the 1980s, but FDA’s July 2026 review found the evidence insufficient for the proposed use — see emideltide and the FDA 503A decision. Persistent anxiety warrants a standard clinical evaluation before any peptide is considered.

Cerebrolysin differs from the others: it is not a single synthetic peptide but a mixture of peptides derived from purified porcine brain proteins, studied in Europe and Asia in stroke recovery, vascular dementia, Alzheimer’s disease, and traumatic brain injury. It is not approved in the US and is not on the FDA tracker.

Dihexa is the most speculative compound in the category. It is an angiotensin IV–derived peptide that promoted synapse formation in rodent models, but it has never been tested in published human trials, has no established human dose, and works through the HGF/c-Met pathway — a pathway that also drives several cancers.

Mitochondrial support is often discussed in the same breath. Methylene blue is not a peptide, but it is studied as an alternative electron carrier in the mitochondrial respiratory chain; its approved use and why low-dose use is off-label are covered in methylene blue dosage.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with a licensed 503A compounding partner. Practices can review the brain and longevity product category and start at For Providers.